250 related articles for article (PubMed ID: 29473173)
21. Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.
Tran JQ; Muench MO; Heitman JW; Jackman RP
Vox Sang; 2019 Apr; 114(3):207-215. PubMed ID: 30734299
[TBL] [Abstract][Full Text] [Related]
22. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
Jackman RP; Lee JH; Pei R; Bolgiano D; Lebedeva M; Slichter SJ; Norris PJ
Transfusion; 2016 Jun; 56(6):1442-50. PubMed ID: 27079754
[TBL] [Abstract][Full Text] [Related]
23. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
24. Clinical aspects of platelet transfusions.
Murphy MF; Waters AH
Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
[TBL] [Abstract][Full Text] [Related]
25. Use of HLA- and HPA--matched platelets in alloimmunized patients.
Kekomäki R
Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
27. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
28. Prevention of platelet alloimmunization.
Slichter SJ
Prog Clin Biol Res; 1986; 211():83-116. PubMed ID: 3515365
[TBL] [Abstract][Full Text] [Related]
29. Management of patients refractory to platelet transfusion.
Chockalingam P; Sacher RA
J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
[TBL] [Abstract][Full Text] [Related]
30. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
[TBL] [Abstract][Full Text] [Related]
31. [Prevention of platelet transfusion refractoriness and HLA alloimmunization by leukocyte filtered platelet transfusion: a meta analysis].
Yuan Q; Chen X; Cheng L; Zhou CH; Fu XM; Li YP; Wang NH; Wang L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):412-20. PubMed ID: 21906451
[TBL] [Abstract][Full Text] [Related]
32. Post-transfusion alloimmunization to granulocytes and platelets in Japanese patients as determined by the MPHA method.
Zhang X; Araki N; Ito K
Transfus Apher Sci; 2001 Dec; 25(3):163-72. PubMed ID: 11846130
[TBL] [Abstract][Full Text] [Related]
33. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients.
Taaning E; Simonsen AC; Hjelms E; Svejgaard A; Morling N
Vox Sang; 1997; 72(4):238-41. PubMed ID: 9228715
[TBL] [Abstract][Full Text] [Related]
34. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
[TBL] [Abstract][Full Text] [Related]
35. Frequency and characterization of platelet-specific antibodies in patients who received multiple platelet transfusions.
Lo SC; Lin DT; Lin SW; Chang JS
J Formos Med Assoc; 2000 Dec; 99(12):902-5. PubMed ID: 11155742
[TBL] [Abstract][Full Text] [Related]
36. How do I … manage the platelet transfusion-refractory patient?
Juskewitch JE; Norgan AP; De Goey SR; Duellman PM; Wakefield LL; Gandhi MJ; Stubbs JR; Kreuter JD
Transfusion; 2017 Dec; 57(12):2828-2835. PubMed ID: 28960321
[TBL] [Abstract][Full Text] [Related]
37. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients.
Schnaidt M; Northoff H; Wernet D
Transfus Med; 1996 Jun; 6(2):111-4. PubMed ID: 8809957
[TBL] [Abstract][Full Text] [Related]
38. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
Sandler SG
Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
[TBL] [Abstract][Full Text] [Related]
39. HLA antigen and antibody association in platelet-alloimmunized patients.
Chow MP; Lin JS; Lin CK; Kuo BI; Yung CH; Lyou JY; Hu HY; Tzeng JL; Lee TD
Zhonghua Yi Xue Za Zhi (Taipei); 1993 May; 51(5):329-32. PubMed ID: 8334558
[TBL] [Abstract][Full Text] [Related]
40. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
Stanworth SJ; Navarrete C; Estcourt L; Marsh J
Br J Haematol; 2015 Nov; 171(3):297-305. PubMed ID: 26194869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
